Growth Metrics

Integra Lifesciences Holdings (IART) Total Current Liabilities (2016 - 2025)

Integra Lifesciences Holdings' Total Current Liabilities history spans 17 years, with the latest figure at $456.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 50.55% year-over-year to $456.0 million; the TTM value through Dec 2025 reached $456.0 million, down 50.55%, while the annual FY2025 figure was $456.0 million, 50.55% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $456.0 million at Integra Lifesciences Holdings, up from $364.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $929.8 million in Q2 2025 and bottomed at $282.3 million in Q1 2023.
  • The 5-year median for Total Current Liabilities is $336.4 million (2021), against an average of $454.8 million.
  • The largest YoY upside for Total Current Liabilities was 203.73% in 2025 against a maximum downside of 60.11% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $340.0 million in 2021, then decreased by 5.62% to $320.9 million in 2022, then dropped by 4.34% to $307.0 million in 2023, then skyrocketed by 200.39% to $922.1 million in 2024, then plummeted by 50.55% to $456.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Total Current Liabilities are $456.0 million (Q4 2025), $364.1 million (Q3 2025), and $929.8 million (Q2 2025).